Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi

Expression of sirtuin 1 and 2 is associated with poor prognosis in non-small cell lung cancer patients (CROSBI ID 220585)

Prilog u časopisu | izvorni znanstveni rad | međunarodna recenzija

Grbeša, Ivana ; Pajares, María J. ; Martínez- Terroba, Elena ; Agorreta, Jackeline ; Mikecin, Ana-Matea ; Larráyoz, Marta ; Idoate, Miguel A. ; Gall Trošelj, Koraljka ; Pio, Ruben ; Montuenga, Luis M. Expression of sirtuin 1 and 2 is associated with poor prognosis in non-small cell lung cancer patients // PLoS One, 10 (2015), 4; e0124670-1-e0124670-17. doi: 10.1371/journal.pone.0124670

Podaci o odgovornosti

Grbeša, Ivana ; Pajares, María J. ; Martínez- Terroba, Elena ; Agorreta, Jackeline ; Mikecin, Ana-Matea ; Larráyoz, Marta ; Idoate, Miguel A. ; Gall Trošelj, Koraljka ; Pio, Ruben ; Montuenga, Luis M.

engleski

Expression of sirtuin 1 and 2 is associated with poor prognosis in non-small cell lung cancer patients

Sirtuin 1 (SIRT1) and sirtuin 2 (SIRT2) are NAD+-dependent protein deacetylases involved in the regulation of key cancer-associated genes. In this study we evaluated the relevance of these deacetylases in lung cancer biology. Protein levels of SIRT1 and SIRT2 were determined in non-small cell lung cancer (NSCLC) cell lines and primary tumors from 105 patients. Changes in proliferation were assessed after SIRT1 and SIRT2 downregulation in lung cancer cell lines using siRNA-mediated technology or tenovin-1, a SIRT1 and SIRT2 inhibitor. High SIRT1 and SIRT2 protein levels were found in NSCLC cell lines compared with non-tumor lung epithelial cells. The expression of SIRT1 and SIRT2 proteins was also significantly higher in lung primary tumors than in normal tissue (P<0.001 for both sirtuins). Stronger nuclear SIRT1 staining was observed in adenocarcinomas than in squamous cell carcinomas (P=0.033). Interestingly, in NSCLC patients, high SIRT1 and SIRT2 expression levels were associated with shorter recurrence- free survival (P=0.04 and P=0.007, respectively). Moreover, the combination of high SIRT1 and SIRT2 expression was an independent prognostic factor for shorter recurrence-free survival (P=0.002) and overall survival (P=0.022). In vitro studies showed that SIRT1 and/or SIRT2 downregulation significantly decreased proliferation of NSCLC. Our results support the hypothesis that SIRT1 and SIRT2 have a protumorigenic role in lung cancer, promoting cell proliferation. Moreover, the expression of these proteins is associated with poor prognosis in NSCLC patients and may help to identify those NSCLC patients with high risk of recurrence that could benefit from adjuvant therapy after resection.

SIRT1; SIRT2; lung cancer; prognosis

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o izdanju

10 (4)

2015.

e0124670-1-e0124670-17

objavljeno

1932-6203

10.1371/journal.pone.0124670

Povezanost rada

Temeljne medicinske znanosti

Poveznice
Indeksiranost